Only 10.2% of radiopharmaceutical clinical trials make it to Phase III. The field is still young. But demand is climbing fast. The system is already straining. Most of the know-how for handling these drugs sits in a few academic centers. Many are maxed out.
This is not just a headache for planners. Radiopharmaceuticals break down quickly. Labs must be close to trial sites. Any holdup in processing can ruin data. That puts entire studies at risk. The old model—one central lab for everything—no longer fits. It cannot keep up with the needs of radiopharmaceutical research.
According to Precedence Research, the radiopharmaceutical sector faces key constraints including a shortage of trained nuclear medicine specialists, isotope supply limitations, and the need for just-in-time logistics due to short half-lives.
Centralized labs can't keep up
Demand for radiopharmaceutical trials is rising. But most sites lack diversity. Too much expertise is stuck in a handful of academic hubs. These centers are full. They cannot take on more studies or expand. This is not theory. It is already slowing research.
The workforce shortage makes things worse. The white paper points to a 40% gap in qualified pharmacists. That means fewer sites can safely handle radiopharmaceuticals. A Becker’s Hospital Review analysis backs this up. It projects a shortage of 30,400 pharmacists in the U.S. by 2038. The talent gap is real. It is hitting radiopharmaceutical logistics hard.
Decentralized, regional lab networks: the new model
The white paper lays out a fix. Build a decentralized, regionally coordinated lab network. Standardize procedures across many labs. This keeps quality high and expands coverage. Targeted training programs would help close the pharmacist gap. More sites could handle radiopharmaceuticals. Readiness would improve.
Automation and AI could help too. They can speed up dosimetry and imaging analysis. That means less manual work and fewer slowdowns. The white paper is blunt. These changes are not optional. The industry needs them to keep up with demand and protect data quality.
A recent industry review highlights that the majority of radiopharmaceutical approvals remain concentrated around Novartis’ Pluvicto and Lutathera, reflecting the early stage of the market and the narrow clinical-commercial base.
Other fields have faced this kind of crunch. As reported earlier, the growth of myositis trials forced a rethink of infrastructure and site readiness. Big players had to adapt. They changed how trials were run.
Radiopharmaceutical trials are at the same point now. The facts are clear. Without decentralized, regionally coordinated lab networks, the field will choke on its own growth. The time to act is now. If the system waits, the next surge in demand could break it—and stall the promise of new therapies.
